RISAPS

Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase IIb, non-inferiority proof of principle trial.

1 March 2024

The RISAPS trial is multi-centre, randomised, open-label trial being done to see if high-intensity rivaroxaban is as effective as high-intensity warfarin which is currently a standard treatment for antiphospholipid patients, with or without lupus, who have had a previous stroke, 鈥榤ini stroke鈥� or other ischemic brain damage.

The Chief Investigator for the RISAPS trial is Professor Hannah Cohen, 香港六合彩中特网H Consultant Haematologist.

This trial is organised by the CCTU at 香港六合彩中特网.

The trial coordination, data collection and analysis and administration will be provided by the CCTU at 香港六合彩中特网.

If you have any questions about this trial you can contact the RISAPS trial manager for further information at email: risaps@ucl.ac.uk.

Trial status:听Closed to recruitment (as of 24 October 2022)
Funder:听Versus Arthritis
ISRCTN:听滨厂搁颁罢狈10280992
First patient recruited on: 15 July 2021
Total patients recruited: 43

听